Study of Combination Therapy With SYR-322
NCT01521962
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
67
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Mellitus
Interventions
DRUG:
Alogliptin
DRUG:
Insulin
Sponsor
Takeda